NASDAQ: TELATela Bio Inc Stock
$5.15-0.02 (-0.39%)
Updated Apr 18, 2024
TELA Price
$5.15
Fair Value Price
N/A
Market Cap
$126.95M
52 Week Low
$4.24
52 Week High
$11.26
P/E
-2.52x
P/B
6.72x
P/S
2.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$58.45M
Earnings
-$46.66M
Gross Margin
68.6%
Operating Margin
-70.9%
Profit Margin
-79.8%
Debt to Equity
3.13
Operating Cash Flow
-$41M
Beta
0.95
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TELA Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TELA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TELA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TELA is poor value based on its book value relative to its share price (6.72x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
TELA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TELA due diligence checks available for Premium users.
Be the first to know about important TELA news, forecast changes, insider trades & much more!
TELA News
Valuation
TELA fair value
Fair Value of TELA stock based on Discounted Cash Flow (DCF)
Price
$5.15
Fair Value
$8.62
Undervalued by
40.26%
TELA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TELA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.52x
Industry
28.61x
Market
41.33x
TELA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.72x
Industry
3.63x
TELA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TELA's financial health
Profit margin
Revenue
$17.0M
Net Income
-$12.9M
Profit Margin
-75.8%
TELA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TELA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$78.0M
Liabilities
$59.2M
Debt to equity
3.13
TELA's short-term assets ($71.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TELA's short-term assets ($71.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TELA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TELA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.1M
Investing
-$193.0k
Financing
$22.0k
TELA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TELA vs Medical Device Stocks
Tela Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.